Coexisting perianal squamous cell carcinoma, Bowen's disease, and condylomata acuminata treated with topical imiquimod 5%

International Journal of Dermatology

Volumn 47, Issue 12, 2008, Pages 1334-1336

  Arregui Murua, Asunción ^a   González, Lucia Carnero ^a   García río, Irene ^a   Urra, Izaskun Trébol ^a   Michelena, Itziar Arrue ^a   González pérez, Ricardo ^a   Catón Santarén, Blanca ^a   Arechavala, Ricardo Soloeta ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; ANUS CARCINOMA; ARTICLE; BEDTIME DOSAGE; BOWEN DISEASE; CASE REPORT; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EROSION; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN TISSUE; PAPULAR RASH; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PUNCH BIOPSY; SKIN DEFECT; SKIN ULCER; SQUAMOUS CELL CARCINOMA; SURGICAL RISK; TREATMENT DURATION; WART VIRUS;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; ANUS DISEASES; ANUS NEOPLASMS; BOWEN'S DISEASE; CARCINOMA, SQUAMOUS CELL; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; SKIN NEOPLASMS;

EID: 57049088647     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03877.x     Document Type: Article

References (6)

1. Ahmed AM, Madkan V, Tyring SK. Human papillomaviruses and genital disease. Dermatol Clin 2006; 24: 157-165.
2. Hengge UR, Benninghoff B, Ruzicka T, et al. Topical immunomodulators: progress towards treating inflammation, infection and cancer. Lancet Infect Dis 2001; 1: 189-198.
3. Egmond SV, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol 2007; 46: 318-319.
4. Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006; 55: 324-327.
5. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003; 121: 1205-1209.
6. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-1332.